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Abstract 
Background: We investigated in postmenopausal women with primary breast cancer prior to surgical intervention 
whether, serum levels of different steroid hormones and hormonal precursors associated with tumor tissue estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status.
Methods: We enrolled 1,042 patients suffering invasive ductal carcinoma undergoing surgical resection in the 
National Institute of Oncology, Hungary between 2003 and 2011. Serum parameters were measured by RIA/IRMA 
assays; tumor tissue ER, PR and HER2 status was assessed histologically. Patients were classified according to tumor 
receptor status. Case–case analysis subjects were categorized into four subgroups based on serum hormone concen‑
trations in ER, PR and HER2 receptor‑negative cases, respectively.
Results: Serum estrone sulfate and dehydroepiandrosterone sulfate levels correlated with each other and also with 
serum estrone and estradiol levels. According to case–case study the odds ratios in the highest quartile were 1.517 
(p = 0.0305, Ptrend = 0.0394) for androstenedione, 1.495 (p = 0.0317, Ptrend < 0.0105) for estrone and 0.654 (p = 0.0273, 
Ptrend < 0.0151) for estrone sulfate/estrone ratio in PR+ vs. PR− tumors. Regarding HER2 status (HER2+ vs. HER2−), 
the odds ratios for estrone, estrone sulfate and estrone sulfate/estrone ratio were 0.530 (p = 0.0234, Ptrend = 0.0595), 
2.438 (p = 0.0042, Ptrend < 0.0066) and 3.118 (p = 0.0001, Ptrend < 0.0001) in the highest quartile, respectively. Of note 
significantly increased BMI associates with PR+ and ER +/PR+ status while significantly decreased BMI was observed 
in HER2+ cases.
Conclusions: Taken together, measurement of serum estrone and estrone sulfate concentrations prior to surgical 
intervention might support the individualization of regime in postmenopausal primary breast cancer patients.
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Background
Breast cancer is a very heterogeneous disease that can be 
classified to molecular, histopathologic and clinical sub-
groups. Anticancer therapy is determined by biological 
characteristics and stage of the tumor. Most important 
biological features determining therapy are endocrine 
sensitivity, human epidermal growth factor receptor 2 
(HER2) expression and proliferative capability of the 
tumor (Láng et al. 2012).
Approximately 70% of breast cancer cases express 
estrogen receptor (ER) and progesterone receptor (PR) 
thus are referred as hormone receptor (HR)-positive. 
HER2 expression is presented in 20–25% of breast cancer 
cases that are classified as HER2-positive (HER2+) (Ross 
et  al. 2009; Dawood et  al. 2010). Approximately 50% of 
HER2-positive cases are also HR-positive (ER+/PR+/
HER2+) (Dowsett et al. 2008; Tripathy et al. 2013; Mehta 
and Tripathy 2014). About 10–20% of invasive breast 
cancer cases do not express ER, PR or HER2 and are 
termed as of triple negative receptor status (ER−/PR−/
HER2−) (Perou 2011; Aysola et al. 2013).
Estrogens play a crucial role in breast cancer progres-
sion through inhibition of apoptosis and stimulation of 
cell proliferation via ER activation (Hankinson and Elias-
sen 2007). Several epidemiological studies indicate that 
plasma estradiol (E2), adrenal androgens and testoster-
one (TE) levels were higher in women who developed 
ER-positive breast cancer later (Key et  al. 2002; Zeleni-
uch-Jacquotte et al. 2004; Missmer et al. 2004; Kaaks et al. 
2005; Cummings et al. 2005; Sieri et al. 2009; Endogenous 
Hormones and Breast Cancer Collaborative Group 2013). 
A Danish population-based prospective study revealed 
that the association between the risk of postmenopausal 
breast cancer and serum estrone (E1) or estrone sulfate 
(E1S) levels is stronger than that between E2 and breast 
cancer risk (Würtz et al. 2012). Zhang et al. (2013) dem-
onstrated that blood sex hormone levels measured at 
a single time-point would predict the development of 
breast cancer within up 16–20 years.
Epidemiological studies focused on the association 
between sex hormones and breast cancers or excluded 
ER-negative breast cancers from the analysis (Key et  al. 
2002; Zeleniuch-Jacquotte et al. 2004; Kaaks et al. 2005; 
Cummings et  al. 2005). The reason of exclusions from 
several cohort studies is that the number of ER−/PR− 
cases was relatively small; the statistical power was insuf-
ficient to assess other relevant breast cancer subtypes, 
such as triple negative, or HER2-positive (Zhang et  al. 
2013).
It is well documented that ER/PR and HER2 status 
predict the clinical outcome and the response to adju-
vant endocrine therapy or poly-chemotherapy. How-
ever, a detailed hormone profile determined before 
surgical intervention can also support to predict the 
hormone sensitivity of the tumor. Based on biological 
and clinical observations it was suggested that plasma 
levels of sulfoconjugated and unconjugated steroid hor-
mones and tissue-specific expression of steroid sulfatase 
(STS) might play a significant role in breast cancer biol-
ogy and might regulate the effects of endocrine therapy 
(Falany and Falany 2007). Kim et  al. found that high 
preoperative serum E2 level indicate worse prognosis 
in postmenopausal women with breast cancer, particu-
larly in those with ER-negative cancer (Kim et al. 2013). 
However, the interaction between sexual hormone lev-
els before surgery and receptor status was not investi-
gated widely.
Our aim was to investigate whether circulating ster-
oid hormone levels including sexual hormones and their 
precursors along with sex hormone binding globulin 
[i.e. E1, E1S, E2, TE, dehydroepiandrosterone (DHEA), 
DHEA sulfate (DHEAS), androstenedione (AD) and 
SHBG] measured prior surgical intervention show any 
association with tumor ER, PR and HER2 status in post-
menopausal women with primary breast cancer. In our 
case–case study the relationship between serum sexual 
hormone levels and tumor ER, PR and HER2 status was 
retrospectively studied using data collected from post-
menopausal patients treated with breast cancer between 
2003 and 2011 in the National Institute of Oncology, 
Hungary.
Methods
Patients
Our study involved 1381 postmenopausal patients with 
primary breast cancer (stages ranging between 0 and 
III). Women were considered postmenopausal when they 
reported not having any menstrual cycles in the past 
24  months; those with bilateral ovariectomy in medical 
history; and those with age above 55 years (Kaaks et al. 
2005).
Distribution of the patients according to age: 485 cases 
(55–59  years), 528 cases (60–69  years), 271 cases (70–
79 years) and 97 cases (≥80 years). The mean age of the 
population studied was 64.7 ± 9.1 years.
The diagnosis of breast cancer was confirmed by his-
tology in all cases. Tumors had been diagnosed by 
experienced pathologists using standard criteria for his-
tology and grading. All patients had resectable stage 
0–III tumors according to the TNM 6.0 staging (Union 
International Cancer Congress, TisN0M0-T2N3M0). 
The histological diagnosis was mainly invasive ductal 
carcinoma (IDC) 1,042 (75.45%), IDC in  situ (DCIS) 84 
(6.08%), invasive lobular carcinoma (ILC) 140 (10.14%) 
and others 115 (8.33%) (including metaplastic, adenoid, 
papillary, apocrine, cribriform, medullary, mucinous and 
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tubular invasive carcinomas). Patients were diagnosed 
mainly with IDC (1,042 cases) therefore statistical analy-
sis was performed within this subgroup.
The study was approved by the Institutional Review 
Board and Ethics Committee of National Institute of 
Oncology, Hungary since 2003. Permission of the Hun-
garian Regional Committee of Science and Research Eth-
ics was obtained for retrospective evaluation of the data 
(Number of permission: 322/2014).
At the time of blood sampling all patients was informed 
about the purpose of our study. Written informed con-
sent was obtained from all individual participants 
included in the study. Patients donated 8–10  ml blood 
sample and completed a questionnaire about reproduc-
tive history, previous use of contraceptives, postmeno-
pausal hormone replacement therapy (HRT). Women 
who used HRT at the last 6  months and/or had a diag-
nosis of cancer within 10 years before surgical interven-
tion were not elected to the present study. Patients who 
received neoadjuvant chemotherapy were excluded, as 
well.
Determination of serum hormone levels
Blood samples were collected according to a standard-
ized protocol. Briefly, the whole blood was centrifuged 
at 2,500  g for 15  min. The serum was removed from 
the blood clot and stored in aliquots at −20°C until the 
determination. Measurements were carried out within 
2–3  months in all cases. Steroid hormone assays were 
performed in our Laboratory on Department of Bio-
chemistry (NIO). Since the concentration of serum 
E2 is usually lower than 40  pmol  l−1 in postmenopau-
sal women, serum E2 level was determined by using an 
ultra-sensitive estradiol radioimmunoassay (RIA) kit 
(Immunotech, Prague, Czech Republic, detection limit: 
8.14  pmol  l−1). E1S, DHEA and AD were measured by 
RIA kit (Immunotech, Prague, Czech Republic). Total TE 
and DHEAS were measured by Immunotech SAS RIA kit 
(Marseille, France); E1 concentration was measured by 
RIA with a Diasource Immunoassays S.A. kit (Louvain-
la-Neuve, Belgium). SHBG was measured by Izinta kit 
(Isotope Institute, Budapest, Hungary). The mean intra- 
and inter-assay coefficient of variations were 7.5 and 9.4% 
for E2, 14.8 and 15.0% for TE, 6.3 and 8.6% for E1, 6.1 and 
4.3% for SHBG, 9.2 and 8.8% for E1S, 5.6 and 9.8% for 
AD, 7.4 and 10.6% for DHEAS, 3.8 and 8.6% for DHEA. 
Stratec SR 300 (Birkenfeld, Germany) an automatic, open 
analyser system was used to detect 125I radioactivity.
Free TE and E2 concentrations were calculated from 
the concentrations of E2, TE and SHBG according to 
previous studies (Vermeulen et  al. 1999; Endogenous 
Hormones and Breast Cancer Collaborative Group 
2003).
Assessment of tumor receptor status
The ER and PR status were evaluated histologically on 
immunohistochemical (IHC) slides [ER: SP1 (NeoMark-
ers), PR: NCL-L PGR-312 (Novocastra)]. ER and PR 
positivity were defined when at least 10% prevalence of 
malignant cells exhibiting staining characteristics.
HER2 protein overexpression was assessed by IHC 
method using three different antibodies: RTV-CB11 
(Novocastra), C-erbB-2/Her-2/neu SP3 clone (NeoMark-
ers) and HercepTest (DAKO). Samples were scored using 
the recommended scoring system for the HercepTest.
HER2 gene amplification was tested with the Inform-
HER2 test by Ventana. The updated cut-off value for pos-
itive cases is more than six copies of the gene. HER2 was 
scored positive if the result was 3+; 2+ was considered 
to be positive only if it was confirmed by fluorescence 
in situ hybridization (FISH).
Statistical analysis
MedCalc Software was used for statistical analysis. In the 
case of a normal distribution, the correlation between 
serum hormone parameters was calculated using the cor-
relation coefficient (r), in the remaining cases Spearman’s 
coefficient of rank correlation (rho) was used. 95% confi-
dence interval (95% CI) for r or rho was computed.
During case–case study hormone receptor-positive vs. 
hormone receptor-negative postmenopausal breast can-
cer patients by quartiles of serum steroid concentration 
were compared. The hormone receptor negative cases 
were categorized into four classes according to hormone 
levels. Receptor-positive/receptor-negative ratio was cal-
culated belong to the four serum hormone concentration 
ranges. Odds ratios (ORs) were computed taking the low-
est category of hormone receptor-negative cases as refer-
ence (Begg and Zhang 1994). ORs with 95% CIs and Ptrend 
are presented by quartile limits of serum parameters.
Chi-square test was used (with Yates’ correction for 
continuity) for the investigation of independence of 
numerical variables and the determination of linear 
trends (Ptrend) among the groups classified by tumor 
receptor status.
Results
Selection of case subjects
IDC patients (1,042 cases) were categorized according to 
histological grade (HG), stadium (St) and ER, PR, HER2 
receptor status (Table 1).
We classified the cases according to their joint sta-
tus of hormone and HER2 receptors. For the case–case 
study we defined the following tumor subtypes: ER+ (852 
cases) vs. ER− (190 cases); PR+ (709 cases) vs. PR− (333 
cases); ER+/PR+ (703 cases) vs. ER−/PR− (184 cases); 
ER+/PR− (149 cases) vs. ER−/PR− (184 cases) and 
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HER2+ (123 cases) vs. HER2− (949 cases) (Table  1). 
In addition, further subgroups were also established 
according to the combined presence/absence of ER, PR 
and HER2. These subgroups were as follows: HER2+/
ER+/PR+ (33 cases) vs. HER2−/ER+/PR+ (670 cases); 
HER2+/ER−/PR− (65 cases) vs. HER2−/ER−/PR− (119 
cases) and HER2−/ER+/PR+ (670 cases) vs. HER2−/
ER+/PR− (125 cases) (Table 1).
Serum hormone levels
Hormone measurements were completed for all 1,042 
cases except E2. Until 2005, the IMMUNOTECH 
RIA kit had been used for serum E2 measurements, 
which had low sensitivity in the range of <40 pmol l−1. 
The values of E2 concentration measured by the two 
different kits significantly differ from each other. 
Therefore, the measurements done with IMMUNO-
TECH RIA kit were excluded from the analysis (392 
subjects).
Later on the serum E2 concentration was measured 
with an ultra-sensitive RIA kit in 650 (62%) patients. 
The average E2 value was 60.53 pmol l−1 (95% CI of the 
mean was 54.97–66.09), therefore this ultra-sensitive kit 
is appropriate for the detection of low serum E2 level in 
the majority of postmenopausal women. Only these data 
were used in the statistical analysis.
Serum concentrations of the steroid hormones corre-
lated significantly with each other. DHEAS significantly 
correlated with DHEA r  =  0.704 (p  <  0.0001), TE/
SHBG ratio r = 0.441 (p < 0.0001) and AD rho = 0.391 
(p  <  0.0001) (data are not shown). Serum E1 and E2 
levels strongly correlated with DHEAS (r  =  0.543, 
p  <  0.0001 and r  =  0.463, p  <  0.0001) (data are not 
shown) and with E1S, the major substrate for STS 
(r = 0.457, p < 0.0001 and r = 0.509, p < 0.0001), respec-
tively (Fig.  1a, b). E1 and E2 correlated significantly 
with each other r = 0.518 (p < 0.0001) and with andro-
gens (AD, free TE) (data are not shown). The associa-
tion between E1 and AD, as well as E2 and TE/SHBG, 
was r = 0.415 (p < 0.0001) and r = 0.433 (p < 0.0001), 
respectively (data are not shown). The serum levels of 
sulfoconjugated steroids (DHEAS, E1S) also correlated 
significantly with each other r  =  0.529 (p  <  0.0001) 
(Fig. 2).
Case–case study
To assess the impact of receptor status on serum steroid 
hormone levels, case–case comparisons and Chi-square 
test were used (OR, 95% CI, Ptrend). IDC patients (1,042 
cases) were categorized into different classes based on 
hormone receptor status as written earlier.
In ER+ vs. ER− tumors the alteration of ORs were sig-
nificant only in case of E1 level (OR = 1.663, p = 0.0026, 
Ptrend = 0.0101) (Table 2).
Our results showed that E1 levels were significantly 
elevated in the fourth quartile of PR+ vs. PR− tumors 
(OR  =  1.495, p  =  0.0317; Ptrend  =  0.0105). The same 
association was observed in case of serum AD levels 
(OR = 1.517, p = 0.0305; Ptrend = 0.0394). Due to asso-
ciation between E1S and E1 levels we examined the 
association between E1S/E1 ratio and hormone recep-
tor status (PR+ vs. PR−). E1S/E1 ratio significantly 
decreased (OR  =  0.654, p  =  0.0273) and a significant 
trend was also present (Ptrend  =  0.0151). There was no 
significant difference in serum E2, TE SHBG concentra-
tions and E2/SHBG ratio. The TE/SHBG ratio showed 
only a significant trend (Ptrend = 0.022). In case of BMI, 
we found a significant elevation in the third (OR = 1.638, 
Table 1 Categorization of  the subjected primary breast 
cancer patients suffering invasive ductal carcinoma (IDC) 
(total number: 1,042) according to histological grade (HG), 
stadium (St) and receptor status
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth 
factor receptor 2.
Factor Number
IDC histological grade (HG) (IDC total number: 1,042)
HG 1 244
HG 2 425
HG 3 373
IDC stadium (St) (IDC total number: 1,042)
1 489
2 336
2a 103
2b 43
3 47
3a 15
3b 2
3c 7
Receptor status (IDC total number: 1,042)
ER+ 852
ER− 190
PR+ 709
PR− 333
ER+/PR+ 703
ER−/PR− 184
ER+/PR− 149
ER−/PR+ 6
HER2+ 123
HER2− 949
HER2+/ER+/PR+ 33
HER2−/ER+/PR+ 670
HER2−/ER+/PR− 125
HER2+/ER−/PR− 65
HER2−/ER−/PR− 119
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p = 0.0487) and fourth quartiles (OR = 1.658, p = 0.0409) 
with a significant trend (Ptrend = 0.0044), as well (Fig. 3).
In ER+/PR+ vs. ER−/PR− cases, the same trend 
(Ptrend = 0.0078) for E1 was observed in the fourth quar-
tile as described in ER+ vs. ER− cases (OR  =  1.766, 
p = 0.0158) (Table 2). Likewise PR+ vs. PR− cases, BMI 
presented the same tendency in the third (OR =  1.639, 
p  =  0.0379) and in the fourth quartiles (OR  =  1.697, 
p = 0.0261) with a positive trend (Ptrend = 0.0244).
This is the first study that investigated associations 
between serum sexual hormones and HER2 status of 
the tumors in invasive ductal breast cancer. HER2 over-
expression (HER2+ vs. HER2−) was assessed with sig-
nificantly decreased E1 levels (OR = 0.530, p = 0.0234). 
Serum E1S levels showed a significant elevation and 
positive trend (Ptrend = 0.0066) in the fourth (OR = 2.438, 
p =  0.0042) quartiles in HER2-positive cases. The ratio 
of E1S/E1 was increased significantly (OR  =  3.118, 
p  =  0.0001) with a positive trend (Ptrend  <  0.0001). In 
addition, AD/E1 ratio also showed significant elevation 
(OR =  1.922, p =  0.0282) in the third quartile, but the 
trend was not seen. BMI significantly decreased in the 
fourth quartile (OR =  0.475, p =  0.0113) and the trend 
was also significant (Ptrend = 0.0027) (Fig. 4).
Contrary to ER+ vs. ER− and ER+/PR+ vs. ER−/
PR− subgroups in HER2−/ER+/PR+ vs. HER2−/
ER+/PR− cases serum E2, E2/SHBG and E1S/E1 ratios 
showed significant or nearly significant trend. OR of E2 
(OR =  1.667) and E2/SHBG (OR =  1.992) increased in 
the fourth quartile; with positive trend (Ptrend =  0.0544, 
Ptrend  =  0.0257). Similar to PR+ vs. PR− cases, OR of 
E1S/E1 decreased to 0.582 in the fourth quartile and 
the trend was nearly significant (Ptrend = 0.0530). OR of 
BMI increased in the fourth quartile (OR = 1.887) with a 
nearly significant trend (Ptrend = 0.0538) (Table 2).
HER2+/ER−/PR− vs. HER2−/ER−/PR− cases did 
not show any significant changes. Interestingly, E1S/E1 
ratio elevated in the fourth quartile (OR  =  2.083) with 
an almost significant positive trend (Ptrend  =  0.0724) 
(Table 2). In addition, AD/E1 (OR = 2.750, p = 0.0387) 
and TE/SHBG (OR =  2.667, p =  0.0363) ratios showed 
significant elevation in the second quartile.
Taking account of hormone receptor (HR) status next 
to HER2 positivity we found the greatest variances in the 
Fig. 1 Correlation between the normal distributed serum con‑
centration of E1S ½ (nmol l−1)½ and E1 ½ (pmol l−1)½ (a) and E1S ½ 
(nmol l−1)½ and E2 ½ (pmol l−1)½ (b). Serum E1 (966 cases) and E2 
(631 cases) levels are significantly correlated with E1S (r = 0.457, 
p < 0.0001 and r = 0.509, p < 0.0001), respectively. Correlation coef‑
ficient (r), 95% confidence and 95% prediction intervals are shown on 
the figure. E1 estrone, E1S estrone sulfate, E2 estradiol, CI confidence 
interval.
Fig. 2 Correlation between the normal distributed serum concentra‑
tion of DHEAS ½ (µmol l−1) ½ and E1S½ (nmol l−1)½. Sulfoconjugated 
steroids, measured in primary postmenopausal IDC breast cancer 
patients (989 cases) prior to surgical intervention, correlated signifi‑
cantly with each other (r = 0.529, p < 0.0001). Correlation coefficient 
(r), 95% confidence and 95% prediction intervals are shown on the 
figure. E1S estrone sulfate, DHEAS dehydroepiandrosterone sulfate, CI 
confidence interval.
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ORs of hormones and SHBG during comparison of HR− 
and HR+ subgroups (HER2+/ER+/PR+ vs. HER2−/
ER+/PR+ and HER2+/ER+/PR+ vs. HER2−/ER−/
PR− comparisons). It should be noted that because of the 
small number of triple positive cases further investiga-
tions are needed.
In the triple-positive vs. HER2−/ER+/PR+ cases the 
OR of E2, E2/SHBG, E1S and E1S/E1 significantly ele-
vated in the fourth quartile with a significant trend except 
E2 where trend was not found. The OR of TE increased in 
the third quartile, while OR of TE/SHBG already elevated 
in the second quartile, but none of them showed a trend 
(Table 2).
The most interesting associations were found in the 
triple-positive vs. triple-negative cases. Significant eleva-
tion was found in case of E2/SHBG, E1S, E1S/E1 and TE 
in the fourth quartile with a significant trend. Serum AD 
also showed significantly elevated OR in the third quar-
tile but the trend was not seen. The OR of BMI decreased 
remarkably without any trend (Table 2).
In ER+/PR− vs. ER−/PR− and HER2−/ER+/PR+ vs. 
HER2−/ER−/PR− cases we did not find any associa-
tion between receptor status and serum steroid hormone 
levels.
Discussion
The strength of our study compared with previous 
reports is the large number of IDC cases (1,042 patients) 
which enables us to evaluate the association between 
serum parameters and receptor status not only in HR-
positive, but HER2-positive and HR-negative cases.
In our study the serum level of steroid hormones, 
hormone-precursors and SHBG were measured prior to 
surgical intervention in postmenopausal women with pri-
mary breast cancer. The associations between E1 and E1S 
and between E2 and E1S and between DHEAS and E1 
indicate the importance of circulating E1S and DHEAS as 
peripheral estrogen pools in serum (Labrie 2015).
After menopause, E2 plasma level decreases by 90% 
(Russo and Russo 2006) and the primary estrogen is E1. 
Others have already reported that serum E2 level is not 
a reliable risk predictor for postmenopausal women. This 
may be due to methodological issues as E2 levels are 
generally around the level of detection in menopause; 
therefore, E1 levels are preferred (Miyoshi et  al. 2003a). 
In patients with diagnosed breast cancer our results for 
E2, E1 and E1S are consistent with literary data (Würtz 
et al. 2012). Based on our case–case studies the serum E1 
concentration and E1S/E1 ratio associated tumor HR and 
HER2 status. Of note, high E1 level and low E1S/E1 ratio 
associate with HR-positivity, particularly PR+ and ER+/
PR+ cases. Regarding HER2, decreased E1 level and 
elevated E1S/E1 ratio were measured in HER2-positive 
cases.
Our results also support the pivotal role of STS in 
peripheral cells (e.g. platelets and lymphocytes) (Bon-
ser et al. 2000; Garrido et al. 2012) and tissues (i.e. nor-
mal breast and breast carcinoma cells). Presumably, 
serum E1S influences intratumoral estrogen biosynthesis 
through STS pathway. STS enzyme activity was detected 
in the great majority of breast carcinomas (Evans et  al. 
1994). In postmenopausal women the sulfatase path-
way is more dominant then the aromatase route. The 
uptake and efflux of sulfoconjugated steroid hormones 
are mediated by transport proteins (Ugele et  al. 2003). 
It was shown that organic anion transport protein 2B1 
Table 2 Case–case comparison of  receptor-positive vs. receptor-negative postmenopausal IDC breast cancer patients 
by quartiles of serum steroid concentrations
Odds ratios in the fourth quartile are shown. Rows in italics present comparisons where number of cases is small therefore these results are only informative. Further 
investigations are needed.
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, E1 estrone, E1S estrone sulfate, E2 estradiol, TE testosterone, AD 
androstenedione, SHBG sex hormone binding globulin, BMI body mass index, OR odds ratio, nd no data.
Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001.
Receptor status Case–case study, odds ratio
E2 
(pmol I−1)
E2/SHBG E1  
(pmol l−1)
E1S  
(pmol l−1)
E1S/E1 AD  
(nmol l−1)
TE  
(nmol l−1)
TE/SHBG BMI 
(kg/m2)
(ER+)/(ER−) 0.82 1.09 1.66** 1.26 0.72 1.24 1.50 1.20 1.12
(PR+)/(PR−) 1.09 1.36 1.5* 1.08 0.65* 1.52* 1.36 1.39 1.66*
(ER+/PR+)/(ER−/PR−) 0.84 1.18 1.77* 1.23 0.66 1.31 1.56 1.29 1.70*
(HER2+)/(HER2−) 1.32 1.99 0.53* 2.44** 3.12*** 0.81 0.99 1.04 0.48*
(HER2+/ER−/PR−)/(HER2−/ER−/PR−) 0.25 1.00 0.56 1.08 2.08 0.71 1.13 1.33 0.46
(HER2−/ER+/PR+)/(HER2−/ER+/PR−) 1.67 1.99 1.38 1.07 0.58 1.51 1.11 1.43 1.89
(HER2+/ER+/PR+)/(HER2−/ER−/PR−) 2.00 9.00* 1.50 17.00** 6.00* 2.14 11.60* 2.25 0.42
(HER2+/ER+/PR+)/(HER2−/ER+/PR+) 6.94 7.00 0.83 17.00* 31.19* 1.22 1.66 2.25 nd
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Fig. 3 Case–case comparison of progesterone receptor‑positive (PR+) vs. progesterone receptor‑negative (PR−) postmenopausal IDC breast 
cancer patients by quartiles of serum steroid concentration. Odds ratios (ORs) were computed taking the lowest category of hormone receptor‑
negative cases as reference. ORs with 95% CIs and Ptrend are presented by quartile limits of serum parameters. Black squares show ORs in quartiles 
(Q1–Q4), and the horizontal lines show 95% CIs. ORs are shown on a log scale. Chi‑square test was used for determination of linear trends (Ptrend) 
among the groups classified by tumor receptor status. ER estrogen receptor, PR progesterone receptor, E1 estrone, E1S estrone sulfate, E2 estradiol, 
TE testosterone, AD androstenedione, SHBG sex hormone binding globulin, BMI body mass index, OR odds ratio, CI confidence interval. Statistics: 
*p < 0.05.
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Fig. 4 Case–case comparison of HER2‑positive vs. HER2‑negative postmenopausal IDC breast cancer patients by quartiles of serum steroid 
concentrations. Odds ratios (ORs) were computed taking the lowest category of hormone receptor‑negative cases as reference. ORs with 95% CIs 
and Ptrend are presented by quartile limits of serum parameters. Black squares show ORs in quartiles (Q1–Q4), and the horizontal lines show 95% CIs. 
ORs are presented on a log scale. Chi‑square test was used for determination of linear trends (Ptrend) among the groups classified by tumor receptor 
status. HER2 human epidermal growth factor receptor 2, E1 estrone, E1S estrone sulfate, E2 estradiol, TE testosterone, AD androstenedione, SHBG sex 
hormone binding globulin, BMI body mass index, OR odds ratio, CI confidence interval. Statistics: *p < 0.05, **p < 0.01, ***p < 0.001.
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(OATP2B1) is responsible for the uptake of E1S in the 
cell (Ugele et  al. 2003). OATP2B1 protein is strongly 
expressed in the epithelial cells in invasive ductal carci-
nomas of the breast. Its expression level correlated with 
the grade and stage of the disease (Al Sarakbi et al. 2006). 
Several studies reported that the expression of STS in 
tumor cells might imply the progression of the tumor 
and indicate a poor clinical outcome (Evans et  al. 1994; 
Utsumi et  al. 1999; Miyoshi et  al. 2003b; Suzuki et  al. 
2009). In addition, increased STS expression has also 
been associated with clinical resistance to endocrine 
therapies (Chanplakorn et al. 2010) and higher histologi-
cal grades (Al Sarakbi et al. 2006; Geisler et al. 2011).
Interestingly in triple receptor-positive cases (HER2+/
ER+/PR+) the elevated steroid hormone concentra-
tions and the significantly increased E1S/E1 ratio com-
pared with HER2−/ER+/PR+ or triple-negative cases 
were associated with HR-positivity and HER2-positivity, 
respectively. This phenomenon might be due to molec-
ular cross-talk between ER and the HER2 pathways 
(Dowsett et al. 2008; Tripathy et al. 2013; Mehta and Tri-
pathy 2014). Several studies indicated that the estrogen-
mediated activation of G-protein coupled ER1 (GPER1) 
was associated with several rapid cellular signaling events 
including activation of epidermal growth factor receptor 
(EGFR) (Filardo et  al. 2006; Ignatov et  al. 2010; Ignatov 
et al. 2011; Jiang et al. 2013). According to De Francesco 
et al. (2014) estrogenic GPER signaling is able to trigger 
hypoxia-inducible factor 1A (HIF1A)-dependent vascular 
endothelial growth factor (VEGF) expression that sup-
ports angiogenesis and progression in breast cancer (De 
Francesco et al. 2014).
Another possible explanation is that estrogens pro-
mote the growth, stromalization and angiogenesis of an 
ER-negative breast cancer cell line (Gupta and Kuper-
wasser 2006; Gupta et  al. 2007). These studies suggest 
that E2 can act as a potent metastasis-promoter in ER-
negative tumors by a novel mechanism involving the host 
microenvironment.
Best to our knowledge we are the first who demon-
strated that elevated E1S concentration and E1S/E1 ratio 
may be linked with HER2-positive tumors and possibly 
may indicate an impact of STS pathway. Because of the 
small number of HER2+/ER+/PR+ cases further investi-
gations are needed to verify this hypothesis.
Our findings that serum E1 level and BMI are signifi-
cantly elevated in PR+ and ER+/PR+ cases is in line 
with literary data and supports the role of aromatase 
route (Cauley et  al. 1989). In HER2+ cases a decreased 
E1 level is associated with a significantly decreased 
BMI. In postmenopausal breast cancer patients obesity-
associated higher estrogen levels might be explain with 
that aromatization is the major source of estrogens in 
contrast to an ovarian source in premenopausal women. 
An increasing volume of adipose tissue in obesity is asso-
ciated with an increase in total body aromatase activity 
(Goodwin 2013). The surrounding adipose tissue has an 
influence to the steroid biosynthesis in the tumor itself. 
Our hypothesis is that instead of aromatase, STS pathway 
will be preferred in HER2+ cases.
These results raise the notion that macro-environmen-
tal concentrations and conversion of conjugated-uncon-
jugated E1 in peripheral tissue and aromatization of AD 
and TE to E1 and E2 in adipose tissue might influence 
the micro-environmental (normal breast) and intrin-
sic (breast tumor) biosynthesis of estrogens. Our result 
draws attention to the importance of STS pathways. 
Measurement of serum E1 and E1S concentrations, and 
their ratio, and the assessment of tumor receptor status 
might support the selection of the appropriate therapy, 
and the individualization of regime.
Therefore, the measurement of serum estrone and 
estrone sulfate concentrations prior to surgical interven-
tion in postmenopausal primary breast cancer patients 
might be of benefit.
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